Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ágnes Ruzsa"'
Publikováno v:
Új Pedagógiai Szemle; 2023, Issue 5/6, p123-126, 4p
Autor:
Erika Hartmann, Zoltán Lóderer, András Vereczkei, György Lázár, Tamás Györke, György Bodoky, Zsuzsanna Papai, Péter Pajor, Oszkár Hahn, Barna Bogner, Károly Kalmár Nagy, Klára Mezei, Elemér Mohos, Zsolt Horváth, Eszter Székely, Magdolna Dank, Attila Doros, P. Á. Deák, Zsuzsa Schaff, Marianna Imre, István Sipőcz, Edit Dósa, Mihály Patyánik, László Mangel, László Harsányi, Péter Kupcsulik, I. Dudás, Péter Bartek, Kristóf Dede, András Papp, Ágnes Ruzsa, Zsolt Káposztás, József Lövey, István Battyáni, Laszlo Torday, Tamás Mersich, Attila Szijártó, Zoltan Mathe, László Sikorszki, László Damjanovich, Krisztina Schlachter, János Révész, Csilla András, Lajos Tóth, László Landherr, János Bezsilla, Erika Hitre, Tibor Csőszi, Zsófia Dankovics, Gábor István, András Palkó, Attila Bursics, András Petri, Ákos Szűcs, László Kóbori, Attila Oláh
Publikováno v:
Orvosi Hetilap. 160:2-20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0726da252c22d364a3a43ce6dc1b376
https://doi.org/10.1556/650.2019.31580
https://doi.org/10.1556/650.2019.31580
Autor:
Barna Budai, László Landherr, Ágnes Ruzsa, Zsuzsanna Kahán, Tibor Csőszi, Károly Máhr, Zsolt Horváth, Katalin Boér, Gábor Rubovszky
Publikováno v:
Pathology and Oncology Research
Purpose: The neoadjuvant use of pertuzumab and trastuzumab with chemotherapy improves the pathologic complete response (pCR) in early HER2+ breast cancer. The aim of this study was to determine the pCR rate obtained with dual HER2 blockade in routine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56a39248c7841d1c99557905b1822de4
https://pubmed.ncbi.nlm.nih.gov/34257621
https://pubmed.ncbi.nlm.nih.gov/34257621
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anikó, Maráz, Katalin, Boér, Zsófia, Dankovics, Magdolna, Dank, Erika, Lahm, Ágota, Petrányi, János, Révész, Ágnes, Ruzsa, Miklós, Szûcs, Anikó, Valikovics, Mária, Vas, Zsófia, Küronya
Publikováno v:
Magyar onkologia. 61(4)
Our aim was to assess the efficacy and adverse effects of cabazitaxel (CBZ), a chemotherapeutic agent that can be administered to patients with metastatic castrate resistant prostate cancer (mCRPC) after docetaxel (DOC) therapy. We retrospectively an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aee4cc03640d088a346a3317849ab048
https://pubmed.ncbi.nlm.nih.gov/29257155
https://pubmed.ncbi.nlm.nih.gov/29257155
Publikováno v:
Orvosi Hetilap. 154:820-824
The incidence of anticipatory nausea and vomiting is 30% among patients receiving repeat chemotherapy.The aim of the authors was to investigate the influence of gender and education level on the incidence of chemotherapy-induced anticipatory nausea a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7e0075e946597c755a68b35b28f7886
https://doi.org/10.1556/oh.2013.29610
https://doi.org/10.1556/oh.2013.29610
Autor:
ANIKÓ, MARÁZ, KATALIN, BOÉR, ZSÓFIA, DANKOVICS, MAGDOLNA, DANK, ERIKA, LAHM, ÁGOTA, PETRÁNYI, JÁNOS, RÉVÉSZ, ÁGNES, RUZSA, MIKLÓS, SZŰCS, ANIKÓ, VALIKOVICS, MÁRIA, VAS, ZSÓFIA, KÜRONYA
Publikováno v:
Magyar Onkologia; 2017, Vol. 61 Issue 4, p353-363, 11p
Autor:
Magdolna Rohánszky, Katalin Varga, Mária Molnár, Piroska Vadász, Ágnes Ruzsa, Eva Balogh, Anna Szekely, Melinda Szöllosi, Katalin Muszbek
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 15(4)
Objectives: The Hospital Anxiety and Depression Scale (HADS) is a widely used screening instrument. The purpose of this study was to evaluate reliability and validity of the Hungarian translation. Methods: The English version of the HADS was translat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53fdfbac526d2ae3720c1273d9b42728
https://pubmed.ncbi.nlm.nih.gov/16688508
https://pubmed.ncbi.nlm.nih.gov/16688508
Autor:
Béla Pikó, László Mangel, Laszlo Budi, József Erfán, Ágnes Ruzsa, László Landherr, Andras Nagy, Jozsef Cseh, Magdolna Dank
Publikováno v:
Journal of Clinical Oncology. 31:e12022-e12022
e12022^ Background: First-line bevacizumab (Bev) combined with paclitaxel (Pac) significantly improves progression-free survival (PFS) and response rate vs. Pac alone in HER2-negative metastatic breast cancer (mBC), as shown in the E2100 study. The e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ecee54cb9301be6884e3c49331cb716
https://doi.org/10.1200/jco.2013.31.15_suppl.e12022
https://doi.org/10.1200/jco.2013.31.15_suppl.e12022
Autor:
Katalin Muszbek, Ágnes Ruzsa
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 4(1)
The authors summarize the developments that have taken place in supportive care in Hungary over the past 20 years. Special emphasis is put on psychological care and care for the terminally ill.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5e77053c6354b039d9d9e5be6ff26b1
https://pubmed.ncbi.nlm.nih.gov/8771287
https://pubmed.ncbi.nlm.nih.gov/8771287